Abzena expands management team: appoints Campbell Bunce to the role of Chief Scientific Officer and Bo Adair as Senior Vice President Process and Operations
Cambridge, UK and San Diego, USA, 28 March 2019 – Abzena, the leading global biologics target to GMP partner research organisation, announced it has appointed Dr Campbell Bunce as Chief Scientific Officer (CSO) and Bo Adair MBA as Senior Vice President Process and Operations. Dr Bunce joined Abzena in November 2015 as SVP Scientific Operations […] Read more
Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development
Cambridge, UK 21 March 2019 – Abzena, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service to assist customers in selecting and developing the best lead candidate […] Read more
Abzena and Lipum AB sign integrated CMC agreement to produce a novel biologic for autoimmune inflammatory diseases
San Diego, USA, 19 March 2019 – Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for […] Read more
ABZENA ANNOUNCES APPOINTMENT OF ELAINE SAPINOSO AS GLOBAL HEAD OF QUALITY
Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule manufacturing San Diego, CA 4 March 2019 – Abzena today announced that it has appointed Elaine Sapinoso as Senior Vice President of Global Quality to support the addition of new manufacturing suites at 2000L scale at its San […] Read more
Abzena Announces Expansion of Integrated Biologics Offering with the Addition of Preformulation and Formulation Capability
Dr. Jonathan Goldman, CEO, Abzena, announced that Abzena has augmented existing discovery to GMP drug substance and Antibody Drug Conjugates (ADC) manufacturing and associated analytical services with numerous investments in preformulation and formulation capabilities to enable de-risking of CTA/IND candidates. Abzena’s existing expertise in analytical assessment of biologics and ADCs is strengthened with the addition of […] Read more
Abzena announces 20m$ investment into expansion of integrated biotherapeutics offering (Biologics Drug Substance and ADC) and makes key executive appointment
Significant increase in capacity to 2000 L scale in new GMP facility, addition of extra cell line development capacity and extra chemistry laboratory space. Appointment of Richard Milbank as Chief Financial Officer. San Diego, CA, Bristol, PA and Cambridge, UK 6th Nov. 2018 – Dr. Jonathan Goldman, CEO, announced that Abzena has augmented existing 500 […] Read more
Ken Cunningham, Chairman of Abzena Limited, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO) following completion of the Acquisition by Welsh, Carson, Anderson & Stowe (WCAS)
Dr. Goldman will focus his efforts on the growth of Abzena as the leading provider of outsourced and integrated services in the biologics early development space by establishing new partnerships with clients, building internal manufacturing capacity and pursuing strategic acquisitions. He joins the company after achieving significant success as the CEO of Aptuit LLC, a […] Read more
Abzena announces a research and licence agreement with Tmunity Therapeutics, a T cell engineering company
Cambridge, UK, 19 September 2018 – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen […] Read more
Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)
Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody™ platform. Faron will develop Clevegen®, a novel anti-Clever-1 antibody, for the treatment of selected metastatic or inoperable tumours. It’s great to see an ABZENA Inside product […] Read more
Update on partial monetisation of ABZENA Inside portfolio
Cambridge, UK, 16 August 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Company’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, confirms that following the announcement today of a recommended cash offer for the Company, it has terminated discussions to sell an interest in its entitlements […] Read more